Navegar por autor "Morano Amado, Luis"

A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection

2013- Morano Amado, Luis

Acute hepatitis C in Spain. Retrospective study of 131 patients

2011- Castro Iglesias, Angeles; Morano Amado, Luis

Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

2019- De Mendoza, C.; Piron, M.; Jimenez, A.; Caballero, E.; Roc, L.; [et al.]

Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

2012- Aguilera Guirao, Antonio; Miralles Alvarez, María Celia; Ocampo Hermida, Antonio; Morano Amado, Luis

Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-alpha for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial

2012- Mariño Callejo, Ana Isabel; Castro Iglesias, Angeles; Morano Amado, Luis; Corredoira Sánchez, Juan

Controlador de élite curado del virus de hepatitis C tras 14 semanas de triple terapia basada en telaprevir

2015- Morano Amado, Luis; Pérez Parente, Diego; Suárez Santamaria, Marta; Suarez Ordoñez, Sandra

Curación de un genotipo mixto, 1b y 4, de hepatitis C tras triple terapia basada en telaprevir

2015- Morano Amado, Luis; Pérez Parente, Diego; Suárez Santamaria, Marta; Suarez Ordoñez, Sandra

Early virological dynamics on genotype 1 & 4 coinfected (HCV/HIV) and monoinfected (HCV) patients treated with peginterferon-alpha 2a plus ribavirin. An interim analysis of the OPTIM study

2012- Morano Amado, Luis

EARLY VIROLOGICAL RESPONSE RATES IN MONOINFECTED PATIENTS WITH HCV AND COINFECTED WITH HCV/HIV, GENOTYPES 1&4 TREATED WITH PEGINTERFERON alpha 2a AND RIBAVIRIN. OPTIM STUDY

2013- Morano Amado, Luis

Effectiveness, safety/tolerability of OBV/PTV/r +/- DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study

2019- Londono, Maria-Carlota; Riveiro-Barciela, Mar; Ahumada, Adriana; Munoz-Gomez, Raquel; Roget, Merce; [et al.]

Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: Final results from startverso1, a randomised, double-blind, placebo-controlled phase III trial

2013- Morano Amado, Luis

Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naive Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial

2013- Morano Amado, Luis

Faldaprevir plus pegylated interferon/ribavirin did not increase anaemia compared with pegylated interferon/ribavirin in HCV genotype-1, treatmentnaive patients: Pooled analysis of phase III studies

2014- Morano Amado, Luis

Hepatitis aguda C en España : estudio retrospectivo de 131 casos

2012- Morano Amado, Luis

Hepatitis C genotype 1b and 4 cured after telaprevir-based therapy

2015- Morano Amado, Luis; Pérez Parente, Diego; Suárez Santamaria, Marta; Suarez Ordoñez, Sandra

IL28B-based model for prediction of early response in patients with hepatitis C genotype 1&4 treated with peginterferon alfa 2a plus ribavirin (P plus R). OPTIM study

2012- Morano Amado, Luis

Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals

2019- Rodríguez Osorio, Iria; Mena de Cea, Alvaro; Meijide Miguez, Hector M; Morano Amado, Luis; Delgado Blanco, Manuel; [et al.]

News on HIV-HCV Coinfection: Update From the 2015 GEHEP Conference

2015- Poveda López, Eva; Morano Amado, Luis

Predictors of hepatitis C treatment failure after using direct-acting antivirals in people living with human immunodeficiency virus

2019- Cachay, E. R.; Mena de Cea, Alvaro; Morano Amado, Luis; Benitez, L.; Maida, I.; [et al.]

Real-world evidence of sofosbuvir/velpatasvir as an effective and simple hepatitis C virus treatment and elimination tool in homeless populations

2022- Conway, B.; Rodriguez-Tajes, S.; Garcia-Retortillo, M.; Pérez-Hernandez, P.; Teti, E.; [et al.]

Repositorio digital RUNA

Navegar por autor "Morano Amado, Luis"

A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection ﻿

Acute hepatitis C in Spain. Retrospective study of 131 patients ﻿

Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain ﻿

Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy ﻿

Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-alpha for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial ﻿

Controlador de élite curado del virus de hepatitis C tras 14 semanas de triple terapia basada en telaprevir ﻿

Curación de un genotipo mixto, 1b y 4, de hepatitis C tras triple terapia basada en telaprevir ﻿

Early virological dynamics on genotype 1 & 4 coinfected (HCV/HIV) and monoinfected (HCV) patients treated with peginterferon-alpha 2a plus ribavirin. An interim analysis of the OPTIM study ﻿

EARLY VIROLOGICAL RESPONSE RATES IN MONOINFECTED PATIENTS WITH HCV AND COINFECTED WITH HCV/HIV, GENOTYPES 1&4 TREATED WITH PEGINTERFERON alpha 2a AND RIBAVIRIN. OPTIM STUDY ﻿

Effectiveness, safety/tolerability of OBV/PTV/r +/- DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study ﻿

Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: Final results from startverso1, a randomised, double-blind, placebo-controlled phase III trial ﻿

Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naive Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial ﻿

Faldaprevir plus pegylated interferon/ribavirin did not increase anaemia compared with pegylated interferon/ribavirin in HCV genotype-1, treatmentnaive patients: Pooled analysis of phase III studies ﻿

Hepatitis aguda C en España : estudio retrospectivo de 131 casos ﻿

Hepatitis C genotype 1b and 4 cured after telaprevir-based therapy ﻿

IL28B-based model for prediction of early response in patients with hepatitis C genotype 1&4 treated with peginterferon alfa 2a plus ribavirin (P plus R). OPTIM study ﻿

Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals ﻿

News on HIV-HCV Coinfection: Update From the 2015 GEHEP Conference ﻿

Predictors of hepatitis C treatment failure after using direct-acting antivirals in people living with human immunodeficiency virus ﻿

Real-world evidence of sofosbuvir/velpatasvir as an effective and simple hepatitis C virus treatment and elimination tool in homeless populations ﻿

A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection

Acute hepatitis C in Spain. Retrospective study of 131 patients

Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-alpha for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial

Controlador de élite curado del virus de hepatitis C tras 14 semanas de triple terapia basada en telaprevir

Curación de un genotipo mixto, 1b y 4, de hepatitis C tras triple terapia basada en telaprevir

Early virological dynamics on genotype 1 & 4 coinfected (HCV/HIV) and monoinfected (HCV) patients treated with peginterferon-alpha 2a plus ribavirin. An interim analysis of the OPTIM study

EARLY VIROLOGICAL RESPONSE RATES IN MONOINFECTED PATIENTS WITH HCV AND COINFECTED WITH HCV/HIV, GENOTYPES 1&4 TREATED WITH PEGINTERFERON alpha 2a AND RIBAVIRIN. OPTIM STUDY

Effectiveness, safety/tolerability of OBV/PTV/r +/- DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study

Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: Final results from startverso1, a randomised, double-blind, placebo-controlled phase III trial

Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naive Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial

Faldaprevir plus pegylated interferon/ribavirin did not increase anaemia compared with pegylated interferon/ribavirin in HCV genotype-1, treatmentnaive patients: Pooled analysis of phase III studies

Hepatitis aguda C en España : estudio retrospectivo de 131 casos

Hepatitis C genotype 1b and 4 cured after telaprevir-based therapy

IL28B-based model for prediction of early response in patients with hepatitis C genotype 1&4 treated with peginterferon alfa 2a plus ribavirin (P plus R). OPTIM study

Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals

News on HIV-HCV Coinfection: Update From the 2015 GEHEP Conference

Predictors of hepatitis C treatment failure after using direct-acting antivirals in people living with human immunodeficiency virus

Real-world evidence of sofosbuvir/velpatasvir as an effective and simple hepatitis C virus treatment and elimination tool in homeless populations